The repeated inhalation vaccine for the global epidemic is expected to become a powerful tool for the prevention and control of Omicron

As the most contagious strain, Omicron has spread rapidly around the world and has quickly replaced Delta as the dominant strain in many places
.

In China, local infection cases of Omicron have appeared in Tianjin, Henan, Zhejiang and other places one after another
.

The high infectivity and hidden transmission characteristics of the Omicron variant can easily break through the current vaccine barrier against infection, which also makes the epidemic prevention measures against it more challenging

The latest research results show that Omicron infection is more concentrated in the upper respiratory tract infection.
In this regard, some professionals have suggested that in order to deal with Omicron strains, it is possible to use inhaled vaccines for mucosal immunity of the respiratory tract, and the effect may be better
.

On a global scale, several inhaled new crown vaccines are also on the horizon, and they are expected to become another important weapon in the global fight against Omicron

The new crown vaccine requires continuous booster shots, and the inhaled vaccine has obvious advantages

The new crown vaccine requires continuous booster shots, and the inhaled vaccine has obvious advantages

Compared with the previous new coronavirus strains, Omicron has many mutation sites and is highly infectious, and most of them focus on infecting the upper respiratory tract rather than infecting the lungs
.

At present, the existing intramuscular vaccines on the market generally only have humoral immunity and cellular immunity.
The vaccine injected on the arm produces antibodies in the blood, but very few antibodies reach our nasopharyngeal mucosa.
The level of antibodies will gradually decline, which means that the immune effect of the vaccine will be weakened, and the new characteristics (high immune escape, infection of the upper respiratory tract) produced by the mutation of strains such as Omicron, so after large-scale vaccination, vaccination with new crown Vaccine booster shots have become a widely promoted policy around the world
.

Generally speaking, vaccines with mucosal immunity are more advantageous for the prevention of respiratory virus infection.
The inhaled new crown vaccine enters the respiratory tract and lungs by inhalation, thereby stimulating the triple protection of mucosal immunity, humoral immunity and cellular immunity
.

Therefore, inhaled vaccines have become a potentially more effective means of dealing with Omicron strains

The results of multiple studies also support this view: a preprint published by the team of Yale University immunologist Akiko Iwasaki, they did experiments in mice and found that the nasal vaccine booster can induce the mucous membrane of the respiratory tract.
Produces powerful antibodies and immune memory cells and enhances protection against primary vaccination
.

In addition, data disclosed by the internationally renowned medical journal "The Lancet" shows that the incidence of adverse reactions after heterologous boosting with inhaled COVID-19 vaccine is lower than that with homologous boosting with inactivated vaccine
.

The immunogenicity results showed that the inhalation boost reached a peak at 28 days, and the level of neutralizing antibodies was significantly higher than that of the inactivated vaccine homologous booster, and 10.
7 times higher than the inactivated homologous booster group 28 days after the booster
.

Twenty-eight days after booster inoculation, no serious adverse reactions occurred in the inhalation group, and no clinically significant pulmonary function abnormalities occurred in the inhalation groups of different doses

Domestic inhaled vaccines are progressing rapidly and are in the first echelon of the world

Domestic inhaled vaccines are progressing rapidly and are in the first echelon of the world

At present, the research and development of inhaled vaccines is in full swing around the world.
Among them, the BBV154 vaccine developed by India's Bharat Company and Washington University in St.
Louis in the United States has entered the clinical phase three earlier this year.
It is expected to Become the world's fastest launch of a new crown vaccine
.

Domestically, following the approved adenovirus vector new crown vaccine Keweisha, CanSino’s inhalation adenovirus new crown vaccine Keweisha has submitted an emergency use application
.

It is undoubtedly in the first echelon in the development of inhaled vaccines in the world

CanSino’s new crown vaccine was jointly developed by the team of Chen Wei, an academician of the Chinese Academy of Engineering of the Academy of Military Sciences, and CanSino.
The inhaled new crown vaccine is no different from the injectable Keweisha vaccine in terms of composition.
The main difference is that the inhaled vaccine uses fog.
The atomizer atomizes the vaccine into tiny particles, which are inhaled into the respiratory tract and lungs, thereby stimulating mucosal immunity, which cannot be brought about by intramuscular injection
.

Recently, an article published online by SSRN, a preprint platform of The Lancet, confirmed that the level of neutralizing antibodies stimulated by sequential boosting of CanSino Bio-Inhaled COVID-19 vaccine was significantly higher than that of inactivated vaccine homologous boosting, 28 days after boosting It is 10.
7 times higher than that of the inactivated homologous enhanced group
.

Global epidemics are repeated, inhaled vaccines may become another important epidemic prevention tool

Global epidemics are repeated, inhaled vaccines may become another important epidemic prevention tool

Since the outbreak of the new coronavirus, the new coronavirus strain has undergone multiple mutations.
After each mutation, the infectivity of the virus has increased, and the main attack site has gradually shifted from the lungs to the upper respiratory tract infection, which is more susceptible to infection.

.

From the perspective of the current global epidemic situation, enhancing the vaccination rate and rapidly developing a targeted vaccine for Omicron is undoubtedly one of the most important tasks
.

The protective efficacy of inhaled vaccines on the upper respiratory tract is significantly better than that of injectable vaccines, and inhaled vaccines are easier to vaccinate than injectable vaccines.

At the same time, the continuous repetition of the new crown epidemic has undoubtedly brought long-term opportunities to the vaccine concept sector
.

In the case that the new crown mutants frequently break through the vaccine protection line of defense, the use of CanSino adenovirus vector vaccine Kwesa for heterologous (sequential) enhanced immunity may become a better solution for China to prevent the epidemic and protect the health of the people

(Original abridged)